Nausea and Vomiting in Advanced Cancer

Navari, Rudolph M.

doi:10.1007/s11864-020-0704-8

Cited by 25 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The etiology of nausea and vomiting in HSCT patients is multifactorial, including delayed gastric emptying, drugs such as opioids, mechanical bowel obstruction, vestibular dysfunction, increased intracranial pressure, metabolic problems and cortical effects such as anxiety and/or depression[ 69 ]. These disorders can lead to dehydration, electrolytic changes and prolonged hospital stays as well as nutrient deficiencies due to inadequate food intake.…”

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

“…The use of behavioral approaches such as relaxation, distraction and relaxation training in addition to utilizing muscle relaxants may be beneficial[ 69 ]. Nutritional recommendations should be adjusted according to the diet tolerance of the patient to relieve nausea and vomiting.…”

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

“…There is insufficient evidence in favor of or against the use of ginger, acupuncture/acupressure and other complementary or alternative therapies for prevention of nausea and vomiting in patients[ 69 ]. However, ginger is considered a medicinal herb that has an important role in preventing nausea (antiemetic properties) in patients undergoing chemotherapy.…”

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

See 2 more Smart Citations

Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update

Akbulut

Yeşildemir

2021

WJSC

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is caused by the newly discovered SARS-CoV-2. Hematopoietic stem cell transplantation (HSCT) is a high-risk procedure. The novelty of COVID-19 has created more uncertainty during all phases of HSCT. It is thought that HSCT patients taking immunosuppressive agents are more likely to contract COVID-19 than healthy individuals are. Appropriate care precautions should be taken with patients undergoing HSCT to minimize the risk of COVID-19, and appropriate treatment methods must be followed in patients infected with COVID-19. Malnutrition has become a significant problem in HSCT patients during the COVID-19 pandemic. The causes of malnutrition in HSCT patients are multifactorial. However, the most important reason is the decrease in energy and nutrient intake. The HSCT procedure can lead to many complications such as dysgeusia, mucositis, diarrhea, constipation, xerostomia and vomiting/nausea. Improving the nutritional status of HSCT patients by managing each of these special complications with an appropriate nutritional approach is essential for successful engraftment. This review aims to provide a comprehensive overview of the specific complications affecting the nutritional status of HSCT patients and their nutritional approach during the challenging COVID-19 pandemic.

show abstract

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update

Akbulut

Yeşildemir

2021

WJSC

View full text Add to dashboard Cite

show abstract

“…cisplatin), as an effective prophylactic when combined with standard 'triple therapy' (5-HT3 + NK1 receptor antagonist + dexamethasone) and if not used prophylactically, as a rescue antiemetic. The addition of olanzapine is recommended because of its ability to further reduce the 'delayed' form of emesis in the days following the first 24h after treatment ('acute' emesis, normally well treated) [43][44][45][46][47][48][49][50]. In one of these studies the 5 mg dose of olanzapine appeared as effective as the 10 mg dose, as measured primarily by the absence of vomiting or retching; nausea was reduced on some but not all days after treatment [44].…”

Section: Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

The Benefits of Olanzapine in Palliating Symptoms

Davis

Sanger

2020

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementOlanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting associated with advanced cancer. The added benefit to olanzapine is that it also stimulates appetite. As a result, since it treats multiple symptoms associated with advanced cancer, it is likely to become the antiemetic of choice in palliative care at least in the United States. The added benefit of treating insomnia and the avoidance of benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients who do complain of insomnia. There is no good evidence that it potentiates the respiratory depression of opioids unlike benzodiazepines. The evidence is weak that olanzapine in as an adjuvant analgesic. Hopefully, future trials will explore this in greater depth. The benefits of adding olanzapine to potent opioids is that it may reduce craving, drug cues and opioid misuse. Other symptoms like anxiety and depression may be addressed by the addition of olanzapine to standard antidepressants.

show abstract

“…Antiemetic treatments act by blocking receptors that are specific to neurotransmitters involved in transmitting the emetic signal to the vomiting center. The main treatments can be classified according to the targeted receptors [21][22][23]:…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%

The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature

Saudemont¹,

Prod’homme

Silva

et al. 2020

BMC Palliat Care

View full text Add to dashboard Cite

Background Olanzapine is an atypical antipsychotic that has affinity for many central nervous system receptors. Its efficacy is supported by several studies in the prevention and treatment of chemotherapy-induced nausea and vomiting. No recommendations exist on the antiemetic use of olanzapine in the palliative care setting. The aim of this work is to complete the initial work of Fonte et al. published in 2015, to determine whether the literature supports the use of olanzapine as an antiemetic in palliative situations and, in practice, to propose a therapeutic schema adapted to the palliative setting. Methods Systematic review of the literature according to the PRISMA criteria. We searched the PubMed, Cochrane, RefDoc, EMBase databases and the gray literature databases. The bibliographic search was conducted between November 2016 and August 2017. Results Thirteen articles were included: 2 case studies, 3 case series, 3 retrospective studies, 2 prospective studies, 2 literature reviews. All studies concluded on the efficacy of olanzapine as an antiemetic in the palliative care setting. No serious adverse effects were reported. Based on the data from the literature review, we propose a therapeutic scheme adapted to the palliative care context. Conclusion Action of olanzapine on many receptors and its tolerance profile make it an interesting antiemetic treatment in palliative medicine. But to date, studies are scarce and have a low statistical power. Further investigation is therefore needed to determine the benefit of this treatment in palliative care patients, compared to usual treatments.

show abstract

Nausea and Vomiting in Advanced Cancer

Cited by 25 publications

References 32 publications

Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update

Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update

The Benefits of Olanzapine in Palliating Symptoms

The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature

Contact Info

Product

Resources

About